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Rationale: Current first-line treatments for stress-related disorders such as major
depressive disorder (MDD) act on monoaminergic systems and take weeks to achieve
a therapeutic effect with poor response and low remission rates. Recent research
has implicated the GABAergic system in the pathophysiology of depression, including
deficits in interneurons targeting the dendritic compartment of cortical pyramidal cells.
Objectives: The present study evaluates whether SH-053-2’F-R-CH3 (denoted “α5-
PAM”), a positive allosteric modulator selective for α5-subunit containing GABAA
receptors found predominantly on cortical pyramidal cell dendrites, has anti-stress
effects.
Methods: Female and male C57BL6/J mice were exposed to unpredictable chronic
mild stress (UCMS) and treated with α5-PAM acutely (30 min prior to assessing behavior)
or chronically before being assessed behaviorally.
Results: Acute and chronic α5-PAM treatments produce a pattern of decreased stress-
induced behaviors (denoted as “behavioral emotionality”) across various tests in female,
but not in male mice. Behavioral Z-scores calculated across a panel of tests designed
to best model the range and heterogeneity of human symptomatology confirmed
that acute and chronic α5-PAM treatments consistently produce significant decreases
in behavioral emotionality in several independent cohorts of females. The behavioral
responses to α5-PAM could not be completely accounted for by differences in drug
brain disposition between female and male mice. In mice exposed to UCMS, expression
of the Gabra5 gene was increased in the frontal cortex after acute treatment and in the
hippocampus after chronic treatment with α5-PAM in females only, and these expression
changes correlated with behavioral emotionality.
Conclusion: We showed that acute and chronic positive modulation of α5 subunit-
containing GABAA receptors elicit anti-stress effects in a sex-dependent manner,
suggesting novel therapeutic modalities.
Keywords: Gabra5, alpha5, depression, interneurons, PAM, GABA
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INTRODUCTION
It is commonly believed that many major psychiatric conditions
are stress-related disorders (Watson et al., 2016). One such
disorder, major depressive disorder (MDD), is a debilitating
illness characterized by several different symptom categories,
including low mood, anhedonia, physiological disturbance,
and increased self-focus and rumination (Ferrari et al., 2013;
Northoff and Sibille, 2014). Lifetime prevalence of MDD is
higher in females than in males, though factors mediating
this increase are still being investigated (Seney et al., 2013).
Frequently, MDD is preceded by and comorbid with other
stress-associated disorders, such as generalized anxiety disorder
(GAD) (Melchior et al., 2007; Moffitt et al., 2007). In fact,
higher occurrence of anxiety disorders in females early in
life can explain some of the increased female risk for MDD
(Breslau et al., 1995). Adding to the disease burden of MDD
is the relative ineffectiveness of conventional antidepressant
medications (roughly 30% remission rates), most of which
act via the monoaminergic system (e.g., selective serotonin
reuptake inhibitors – SSRIs) (Cipriani et al., 2009; Rush, 2010).
Although drugs with rapid acting antidepressant effects have
shown promise in preclinical studies and effectiveness in treating
severely depressed individuals (Li et al., 2010; Zarate et al.,
2012a,b), no existing antidepressant drug directly addresses the
pathology observed in the depressed brain, providing a potential
explanation for the limited efficacy of current antidepressants.
Converging evidence has long suggested a role for the
inhibitory neurotransmitter gamma-amino butyric acid (GABA)
in the pathophysiology of depression (Krystal et al., 2002; Luscher
et al., 2011). Studies using magnetic resonance spectroscopy show
decreases in GABA levels in depression in brain regions critical
for emotion regulation [dorsolateral prefrontal cortex (dlPFC),
subgenual anterior cingulate cortex (sgACC)] (Sanacora et al.,
1999, 2004; Bajbouj et al., 2006). At the cellular level, reduced
density of calbindin-positive interneurons were reported in
frontal cortex (Rajkowska et al., 2007). At the molecular level, we
previously reported alterations in GABA-related gene expression
in dlPFC, sgACC, and amygdala (Sibille et al., 2010; Tripp et al.,
2011; Guilloux et al., 2012; Seney et al., 2014). Preclinical evidence
has also implicated the GABA system in the development of
stress-induced (i.e., anxiety- and depressive-like) behaviors. Mice
with reduced GABA signaling exhibit increased depressive-like
behavior (Earnheart et al., 2007; Shen et al., 2010). Further,
chronic stress paradigms that produce anxiety- and depressive-
like behavior in rodents cause GABAergic deficits in the frontal
cortex, including decreases in major GABA synthesizing enzymes
(Herman and Larson, 2001; Gilabert-Juan et al., 2013).
Interestingly, this alteration in GABAergic signaling in MDD
subjects appears to be restricted to interneuron subtypes that
project to the dendritic compartment of cortical pyramidal
cells, as characterized by the expression of somatostatin (SST),
neuropeptide Y (NPY) and cortistatin (CORT) neuropeptides
(and that co-express calbindin); Cells targeting the perisomatic
compartment, such as parvalbumin (PV)- or cholecystokinin
(CCK)-expressing GABA neurons appear only sparingly affected
(Sibille et al., 2010; Tripp et al., 2011; Guilloux et al., 2012).
Recent work in mice has demonstrated that cortical SST cells are
also affected in the unpredictable chronic mild stress (UCMS)
model which induces elevated behavioral emotionality, and that
UCMS-induced anxiety- and depressive-like behavior can be
recapitulated in mice lacking SST (Lin and Sibille, 2015), together
suggesting a causal link between low SST expression and elevated
behavioral emotionality. The UCMS model has been used to
assess potential drug targets for treating human depression, as it
has good construct (stress precipitates the UCMS phenotype as
well as MDD episodes and disrupts similar biological pathways),
predictive (chronic treatment with SSRIs reverses the UCMS
phenotype), and face validity (behavioral features replicated)
(Edgar et al., 2011; Isingrini et al., 2012; Lin and Sibille, 2015).
Importantly, the structured anatomical distribution of
GABAA receptors in the cortex provides a potential means
of directly addressing GABAergic dysfunction within a
specific compartment. Specifically, α5-containing GABAA
receptors are predominantly expressed on dendritic branches
of pyramidal cells where they mediate dendritic inhibition
in vitro (Wainwright et al., 2000; Ali and Thomson, 2008),
whereas α1- and α2-containing GABAA receptors are found
near the soma (Packer et al., 2013). This anatomical proximity
suggests a functional link between dendrite-preferring SST
cells and the extra-synaptic α5-containing GABAA receptors
that mediate tonic inhibition in the cortex (Bonin et al., 2007;
Brickley and Mody, 2012). Knowing that GABA signaling is
decreased in MDD and similarly in the rodent UCMS model, we
set out to test whether increasing GABAergic tone specifically
at the dendritic compartment may reverse UCMS-induced
behaviors, a hypothesis supported by recent restriction of
function experiments suggesting the α5 subunit contributes
to the anxiolytic effects of diazepam, a non-selective positive
allosteric modulator (PAM) of GABAA receptors (Behlke et al.,
2016). To directly test this hypothesis, we utilized the GABAA
receptor subtype-selective PAM, SH-053-2’F-R-CH3 (denoted
further as α5-PAM), which has high affinity for GABAA receptors
containing the α5 subunit (Ki = 95.2 nM) and lower affinity
for GABAA receptors containing the α1- (Ki = 759.1 nM),
α2- (Ki = 948.2 nM), and α3-subunits (Ki = 768.8 nM) (Savic
et al., 2010). Based on the hypothesis that UCMS reduces
GABAergic efficacy at the dendritic compartment, we predicted
that enhancing GABA tone with α5-PAM would reverse
UCMS-induced behavior in female and male mice.
Crucially, chronic stress procedures, including UCMS,
disrupt multiple facets of the anxiety-/depressive-like behavioral
spectrum in rodents (Willner, 2005). Likewise, MDD, as
assessed by traditional clinical rating scales (e.g., Hamilton
Depression Rating Scale), is typified by depressive, anxiety, and
physiological/somatic symptoms that are mostly convergent on
a syndrome rather than consistent within symptom dimension
across time (Overall and Rhoades, 1982; Oquendo et al., 2004).
The syndrome aspect of stress-induced disorders highlights the
need to evaluate a battery of stress-induced behaviors in a
single animal, which can then be quantified on the individual
test level or as a composite “behavioral emotionality” score,
analogous to an overall clinical rating score. Although this is
rarely taken into consideration in rodent studies, it can be
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operationally accomplished using standard behavioral Z-scoring
methods (Guilloux et al., 2011), as applied in this study. This
approach has been used with success to characterize stress-
associated behavioral changes in rodents (Edgar et al., 2011;
Soumier and Sibille, 2014; de Sa-Calcada et al., 2015; Lin and
Sibille, 2015; Quesseveur et al., 2015; Anacker et al., 2016).
MATERIALS AND METHODS
Animals
For behavioral experiments, adult (8 weeks old) C57BL/6J mice
(Jackson Laboratories, Bar Harbor, ME, USA) were housed under
standard conditions with a 12/12 light/dark cycle (prior to
UCMS) and ad libitum access to food and water in accordance
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals, and approved by University of Pittsburgh
Institutional Animal Care and Use Committee.
Unpredictable Chronic Mild Stress
(UCMS)
Mice underwent between 6 and 8 weeks of UCMS (see
Supplementary Table S1 for example UCMS schedule). Animals
were exposed to 2–3 mild stressors each day throughout the
light/dark cycle, including wet bedding, brief restraint, forced
bath, no bedding, reduced space, and predator odor over a period
of several weeks (see details in Supplementary Material) (Edgar
et al., 2011; Lin and Sibille, 2015). Female mice were housed 5 per
cage, and male mice were housed 4 per cage in Optimice cages
(Animal Care Systems Inc, Centennial, CO, USA). In experiment
3.4, UCMS was augmented with single-cage isolation housing
in male mice beginning at the fourth week of UCMS until
sacrifice. A timeline of experimental procedures can be found in
Figure 2A (including timeline of the sections “ Drug Treatment”
and “Behavioral Testing”).
Drug Treatment
At the start of the third week of UCMS and continuing
for between 28 and 42 days (including time for behavioral
tests, see “Behavioral Testing”) until sacrifice, mice received
daily i.p injections of vehicle (85% ddH2O, 14% propylene
glycol, 1% Tween 80) or 30 mg/kg SH-053-2’F-R-CH3 (α5-
PAM; synthesized in the laboratory of Dr. James M. Cook) in
a volume of 10 mg/mL. All animals received a single daily
injection (chronic α5-PAM treated mice received SH-053-2’F-
R-CH3, acute α5-PAM and vehicle treated animals received
vehicle injections) between 8:00AM and 9:00AM until the start
of behavioral testing. After 3 weeks of treatment, all mice began
receiving a second injection 30 min prior to behavioral testing. All
animals received a second injection of either vehicle (for chronic
α5-PAM treated animals and UCMS-vehicle treated animals)
or α5-PAM acutely (α5-PAM acute animals). All injections
were performed using ultra-fine insulin syringes (31 gauge,
6 mm; Becton, Dickinson and Company, Franklin Lakes, NJ,
USA).
Behavioral Testing
After 5 weeks of UCMS, including 3 weeks of drug treatment,
animals were assessed in a battery of behavioral tests (each
test separated by 48 h, UCMS continued throughout behavioral
testing for a period of 1–3 weeks). These tests included: Elevated
plus maze: under red light, animals were placed on a plus maze
with two open and two closed arms (30 cm × 5 cm). Number
of entries into all arms as well as the time spent in the open
arms was recorded for 10 min. Open field test: The open field test
was conducted in a 43 cm ×43 cm arena under bright (800 lux)
light. Using AnyMaze software (Stoelting, Wood Dale, IL, USA),
the center 50% of the arena was identified and animals were
tracked for 10 min. Novelty suppressed feeding test: Mice were
food deprived for 24 h the day before testing. Testing occurred
in brightly lit (∼1000 lux) open field arenas covered in bedding.
A normal food pellet was placed into the brightly lit center
and the latency for an animal to approach and bite the pellet
was recorded over a 12 min session. Immediately following the
session, animals were placed into their home cage and allowed to
eat a weighed food pellet to assess hunger drive. Cookie test: The
cookie test apparatus contains three identically sized chambers
(40 cm × 20 cm × 20 cm) separated by two offset dividers. The
outer walls of each chamber were clear and the only difference
between each was the color of the divider, with one divider shaded
white and the other black. One week prior to experimentation,
mice were habituated in their home cage to a piece (2 ± 1 g) of
Keebler Fudge Stripe Cookie (Kellogg’s Company, Battle Creek,
MI, USA). On the first and second day of testing, a piece of
cookie (2 ± 1 g) was placed into the chamber separated by the
black divider. Mice were then placed into the opposing chamber
separated by the white divider and monitored for 10 min. The
latency for each mouse to bite the cookie was recorded. Data from
day two of the cookie test are presented, after mice acclimated
to the anxiogenic environment and their behavior is driven
more prominently by reward-seeking, resulting in a decrease
in latency to bite (Isingrini et al., 2011; Soumier and Sibille,
2014).
Pharmacokinetic Study of α5-PAM
Adult (8 weeks old) male and female C57BL/6J (Military Farm,
Belgrade, Serbia) were divided into six groups corresponding to
pre-determined time intervals following a single 30 mg/kg α5-
PAM injection (5, 10, 20, 40, 60, and 180 min). At 30 mg/kg
α5-PAM administration has high affinity for the α5-subunit and
lower affinity for GABAA-receptors containing other subunits
(Savic et al., 2010). As the goal of this study was to selectively
evaluate positive modulation of α5-containing GABAA receptors
to stress-induced behaviors, we chose this dose to conduct
preliminary pharmacokinetic analyses. Blood samples were
collected in heparinized syringes via cardiac puncture of mice
anesthetized with ketamine (100 mg/kg i.p.; 10% Ketamidor,
Richter Pharma Ag, Wels, Austria), and centrifuged at 2500 rpm
for 10 min to obtain plasma. Thereafter, mice were decapitated
and brains were weighed, homogenized in 2 mL of methanol
and centrifuged at 6000 rpm for 20 min. To determine the
concentration of α5-PAM in plasma and supernatants of brain
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tissue homogenates, α5-PAM was extracted by solid phase
extraction using Oasis HLB cartridges (Waters Corporation,
Milford, MA, USA). The procedure of sample preparation
and determination of α5-PAM by ultra performance liquid
chromatography–tandem mass spectrometry (UPLC–MS/MS)
with Thermo Scientific Accela 600 UPLC system connected to a
Thermo Scientific TSQ Quantum Access MAX triple quadrupole
mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA)
equipped with electrospray ionization (ESI) source, is described
in Obradovic et al. (2014).
Plasma Protein and Brain Tissue Binding
Studies
The rapid equilibrium dialysis assay used to determine free
fraction of α5-PAM in mouse plasma and brain tissue was the
same as in Obradovic et al. (2014).
Tissue Samples and Micropunch
Procedure
Twenty-four hours after the final behavioral test, mice were
injected with either an acute dose of α5-PAM or vehicle
30 min prior to rapid perfusion (2 ml 4%PFA). Brains were
rapidly dissected and flash frozen on dry ice. 160 µm thick
coronal sections were obtained using a cryostat. The prelimbic
cortex and dorsal hippocampus were dissected with a 1 mm
diameter micropunch and tissue samples were then frozen
at −80◦C. Total RNA was extracted with an RNAeasy FFPE
kit (Qiagen, Germantown, MD, USA) and tested for purity
on a NanoDrop Spectrophotometer (260/280 ≥ 1.9). RNA
concentration and integrity (RIN > 7) were then assessed using
the Agilent RNA6000 Pico-Kit and Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA).
Real-Time Quantitative PCR
Approximately 90 ng of total RNA was used to generate cDNA via
the qScriptTM cDNA Supermix synthesis kit (Quanta Biosciences,
Gaithersburg, MD, USA). Real-time quantitative polymerase
chain (qPCR) reactions were carried out using SYBR green
fluorescence signal (Invitrogen, Carlsbad, CA, USA) and an
Opticon Monitor DNA Engine (Bio-Rad, Berkeley, CA, USA).
Gene of interest was the α5-subunit of the GABAA receptor
(Gabra5). Samples were run in triplicate and 1Ct values were
calculated by comparing the Ct values of Gabra5 to the geometric
mean of two reference genes, β-Actin and glyceraldehyde 3-
phosphate dehydrogenase (Gapdh). Arbitrary signal intensity was
calculated as 2−1Ct∗10,000.
Surface Biotinylation
Dissected hippocampi were processed as described in Pabba et al.
(2014) with minor modifications.
Antibodies
The following antibodies and their dilutions were used in this
study: rabbit polyclonal anti-α5 (1:750; Thermo Fisher Scientific,
Waltham, MA, USA), rabbit monoclonal anti-β1-N+/K+-ATPase
(NK-ATPase) (1:1000; Abcam, Cambridge, MA, USA), and
mouse monoclonal anti-β-actin (1:100; Abcam, Cambridge, MA,
USA).
Western Blotting
Western blotting was performed using 5 µg of protein resolved
on 8% SDS-PAGE and transferred onto PVDF membranes and
developed using IR-Dye conjugated secondary antibody and
detection using LI-COR (NE, USA). Quantification of bands
was performed using Image StudioTM Software (LI-COR, NE,
USA). We analyzed α5 surface biotinylation in vehicle versus
drug treated mice (N = 6 females and 4 males per group). Total
α5 band intensities were normalized to β-actin, whereas surface
α5 band intensities were normalized to NK-ATPase.
Z-Score Generation and Statistical
Analysis
To assess the consistency of effects of stress and drug treatment
on overall stress-induced behavior, we calculated behavioral
z-scores using the formula below. These normalized scores
integrate measures of behavioral dimensions (e.g., emotionality)
over time and tests, yielding a combined measure of the UCMS-
induced behavioral syndrome (Guilloux et al., 2011).
Z = X − µ
σ
Briefly, for each behavioral measure a Z-score was calculated for
an individual animal indicating how many standard deviations
(σ) a given observation (X) is from the mean of the control
group (µ). These scores were averaged within test such that each
test had the same weight, and then averaged across all four tests
(EPM, OFT, NSF, cookie test) to obtain a composite emotionality
Z-score for each mouse. In short, random or opposite behavior
across tests yield null z-scores, whereas significant and/or trend-
like behaviors across tests and consistently in the same directions
yield high z-scores.
Behavioral and gene expression data were analyzed with a
two-way (sex × treatment) or one-way analysis of variance
(ANOVA). The Holm–Sidak correction was used to determine
group differences only following a significant main effect or
interaction in the ANOVA model. In one specific experiment
(see “α5-PAM Has No Anti-stress Properties in Male Mice Even
after Augmenting UCMS with Single Housing and Increasing the
Dose of α5-PAM”) a priori predictions led to planned comparison
using unpaired two-tailed t-tests of UCMS-vehicle treated mice
and non-stressed (NS-) vehicle treated mice.
RESULTS
Systemic Administration of α5-PAM
Leads to Rapid Increase in Brain Levels
in Female and Male Mice
Free concentrations of α5-PAM were calculated by multiplying
the total plasma and brain concentrations with the appropriate
free fractions (7.44% for plasma and 2.73% for brain tissue)
determined by rapid equilibrium dialysis. Two-way repeated
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measure ANOVA for total brain concentration revealed a
statistically significant difference between female and male
mice [F(1,4) = 7.83, p < 0.05], and between time points
[F(5,20) = 6.89, p < 0.001] with no significant interaction
[F(5,20) = 1.05, p > 0.05]. α5-PAM plasma concentration were
higher in female than male mice [F(1,4) = 16.54; p < 0.05] with
a significant effect of time [F(5,20) = 12.27, p < 0.001] and no
interaction [F(5,20) = 1.02, p > 0.05]. Post hoc comparisons
revealed significant differences between female and male mice
in plasma Cmax [t(4) = −3.04, p < 0.05, Figure 1], confirming
that higher concentrations were obtained in female mice.
Furthermore, the AUC0−3 in brain is approximately 1.25X higher
for females (4910.13 ± 1032.02) than males (3944.49 ± 560.30),
suggesting that a cumulative 25% more ligand is available in the
brain of female mice, after the same dose. However, at 30 min,
the amount of ligand in the brain of male and female mice
was not statistically different (Figure 1). For this reason, we
initially chose the 30 mg/kg dose and 30 min time point for
evaluating the acute behavioral effects of α5-PAM in male and
female mice. In behavioral experiments, acute treated male and
female mice received a 30 mg/kg injection of α5-PAM with 48 h
in between, when no existing compound remained in plasma or
brain in either male or females based on t1/2 (Figure 1). Thus, we
consider this an acute treatment prior to each behavioral test (See
Discussion).
α5-PAM Reduces the Stress-Induced
Behaviors in Female, but Not Male Mice
We first sought to examine whether acute or chronic α5-PAM
treatment would have an anti-stress effect in female and male
mice exposed to UCMS. Due to the large number of mice (total
N = 54) and necessity for randomness of stressors in order to
produce a robust UCMS effect (Guilloux et al., 2011), as well as
the reported lack of baseline (non-stressed) effects of α5-PAM
(Savic et al., 2008, 2010), we did not include non-stressed mice in
this initial experiment (see “α5-PAM Reduces the Stress-Induced
Behavioral Emotionality of Female Mice to Non-stressed Control
Levels” and “α5-PAM Has No Anti-stress Properties in Male
Mice Even after Augmenting UCMS with Single Housing and
Increasing the Dose of α5-PAM” for non-stressed comparisons).
Figure 2A illustrates a timeline of all experimental procedures.
In the EPM, we found a significant interaction between sex
and treatment [F(2,48) = 4.094, p < 0.05], with post hoc
analysis revealing that chronic α5-PAM treatment exhibiting an
anti-stress effect on the percentage of entries into open arms
(Figure 2B). No significant differences were observed in male
mice following stress (p> 0.05). In the OFT, we did not detect any
significant main effects (Figure 2C; p > 0.05) or an interaction
between effects (p > 0.05). While EPM and OFT measures are
corrected for changes in locomotion, it is important to note that
no main effect of treatment, sex, or interaction on locomotion in
the OFT was observed (Supplementary Figure S1C; p> 0.05).
We next examined the anti-stress properties of α5-PAM
in the NSF, typically robustly affected by UCMS (Lin and
Sibille, 2015), and cookie test, which taps into the anhedonic
dimension of stress-induced symptoms. In the NSF, we again
observed a significant interaction between sex and treatment
[F(2,48) = 3.930, p < 0.05] and a similar pattern of behavior
in female mice, with acute (p < 0.01) and chronic (p < 0.05)
α5-PAM treatment reducing latency to bite compared to UCMS-
vehicle treated animals. Again, no effect of either acute or chronic
α5-PAM was observed in male mice (Figure 2D; p > 0.05).
Importantly, neither sex [F(1,48) = 1.344, p > 0.05] nor α5-
PAM treatment [F(2,48)= 1.721, p> 0.05] altered the percentage
of weight lost after 24 h of food deprivation prior to the NSF
test with no interaction between the two factors [Supplementary
Figure S1A; F(2,48) = 1.775, p > 0.05]. Likewise, there was no
effect of treatment on the amount of normal chow consumed
in the home cage 8 min after the NSF [Supplementary Figure
S1B; F(2,48) = 1.441, p > 0.05], though males did consume
more relative to females [F(1,48) = 4.061, p < 0.05]. Together,
this suggests that differences in latency to bite are not due to
a non-specific effect of treatment on hunger. In the cookie test,
two-way ANOVA indicated a significant main effect of treatment
[F(2,48) = 3.504, p < 0.05]. Follow-up comparisons uncovered
a significant decrease in latency to bite the cookie in female
mice following chronic α5-PAM administration (p < 0.05). No
significant difference in latency to bite was observed in male mice
after acute or chronic α5-PAM treatment (Figure 3E). Given
significant overlap between anxiety and depression behavior in
both humans and rodents, we examined the combined anti-stress
effect of α5-PAM on emotionality behavior via Z-normalization
across tests (Figure 2F). We found a significant main effect of
sex [F(1,48) = 19.66, p < 0.05] and an interaction between sex
and treatment [F(2,48) = 4.927, p < 0.05]. Subsequent multiple
comparisons revealed an anti-stress effect of chronic (p < 0.05)
and acute α5-PAM (p < 0.05), but no effect in male mice
(Figure 2E; p > 0.05). Together, these data indicate that acute
and chronic treatments with α5-PAM result in a rapid reduction
of stress-induced behaviors in female but not in male mice.
α5-PAM Reduces the Stress-Induced
Behavioral Emotionality of Female Mice
to Non-Stressed Control Levels
Our first exploratory experiment suggested that treatment with
α5-PAM has anti-stress activity in UCMS-exposed female mice.
Therefore, we sought to replicate these findings in a separate
cohort of female mice. Specifically, we asked whether acute
or chronic treatment with α5-PAM could reverse UCMS-
induced emotionality behaviors back to levels measured in
non-stressed control mice. In the EPM a significant effect
of treatment was observed in the percentage of crosses an
animal made into the open arms [F(3,66) = 5.069, p < 0.01].
Post hoc comparisons indicated that UCMS-vehicle treated
animals spent a smaller percentage of time in the open
arms compared to non-stressed vehicle animals (Figure 3B;
p < 0.001), although no effect of either acute or chronic α5-
PAM treatment was observed (p > 0.05). In the OFT, mice
treated chronically with α5-PAM had a higher percentage of
their total distance traveled (Figure 3B; p < 0.01) in the
center of the arena compared to vehicle-treated UCMS-exposed
animals.
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FIGURE 1 | Pharmacokinetic analysis of α5-PAM brain and plasma levels in female and male mice. Brain (main figure) and plasma (inset)
concentration–time profiles of α5-PAM (30 mg/kg) after intraperitoneal administration (n = 3 per time point), with estimated free brain concentration in female and
male mice. ∗p < 0.05 between female and male mice in different time-points, according to Tukey post hoc test after two-way repeated ANOVA. The calculated
plasma and brain pharmacokinetic parameters of α5-PAM are tabularly presented on the right. ∗p < 0.05 between female and male mice according to t-test.
In the NSF test, a significant effect of treatment was
observed in the latency to bite the food pellet [F(3,66) = 7.261,
p < 0.001]. Post hoc comparisons indicated that UCMS-
vehicle treated animals took longer to bite the food
pellet than non-stressed vehicle animals (p < 0.05), and
that both acute (p < 0.001) and chronic (p < 0.01) α5-
PAM treatments reduced the latency to bite compared to
UCMS-vehicle mice (Figure 3C). In the cookie test, there
was a significant effect of treatment [F(3,66) = 3.065,
p < 0.05] with post hoc comparisons revealing both acute
(p < 0.05) and chronic (p < 0.05) α5-PAM treatment
significantly reduced the latency to bite the cookie
(Figure 3D).
Although the effect of stress was not consistent across
all tests, we observed a convergent effect of UCMS on
Z-emotionality scores [F(3,66)= 7.125, p< 0.001], with post hoc
comparisons highlighting an increase in behavioral emotionality
of UCMS-vehicle treated animals compared to non-stressed
vehicle animals (Figure 3E; p < 0.001). Acute (p < 0.001)
and chronic (p < 0.001) α5-PAM treatment significantly
decreased stress-induced Z-emotionality scores compared to
the UCMS-vehicle group. The acute and chronic α5-PAM
treatment groups were not statistically different from the non-
stressed vehicle group (Figure 3E; p > 0.05). Together these
findings replicated and confirmed the prior results suggesting
an anti-stress effect of α5-PAM in female mice (Figure 2) and
highlight the value of z-scoring at identifying consistent and
convergent behavioral changes within mouse across multiple
tests.
α5-PAM Has No Anti-Stress Properties in
Male Mice Even After Augmenting UCMS
with Single Housing and Increasing the
Dose of α5-PAM
Similarly as for the effect in female mice, we sought to replicate
the lack of α5-PAM effect observed in our preliminary study in an
independent cohort. Moreover, given the inherent variability of
the UCMS paradigm and the fact that the phenotype can be more
robust in female compared to male mice (Guilloux et al., 2011),
we conducted an experiment in which we single-housed male
mice for the final 2 weeks of UCMS and throughout behavioral
testing to potentiate UCMS-induced phenotypes, as previously
described in Surget et al. (2009) and Ma et al. (2011). As shown in
Figure 4A, planned comparisons indicate that the combination of
UCMS and social isolation did not affect behavior in the EPM, but
resulted in a decrease in the percent distance traveled in the center
of the OF [t(22) = 2.184, p < 0.05], increased latency to bite a
food pellet in the NSF [t(22) = 2.088, p < 0.05], and increased
latency to bite in the cookie test [t(22) = 2.075, p < 0.05]
relative to non-stressed vehicle-treated animals. Consistent with
our prior observations, chronic treatment with α5-PAM did not
alter the UCMS-induced behavioral phenotype of male mice in
either the EPM, OFT, NSF or cookie test (Figure 4A; p > 0.05).
Summary emotionality Z-scores indicated that combined UCMS
and isolation housing robustly increases emotionality behavior
in male mice compared to non-stressed controls [Figure 4D;
t(22) = 3.331, p < 0.01], and confirmed the lack of effect of
chronic α5-PAM treatment in male mice [p> 0.05].
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FIGURE 2 | Effect of α5-PAM on stress behavior induced by UCMS in
female and male mice. (A) Timeline of experimental procedures. Tick marks
indicate the beginning of a week. Depending on number of animals,
behavioral testing took between 1 and 3 weeks. (B) Female mice treated with
α5-PAM chronically had increased percentage of open arm entries relative to
UCMS-VEH mice, with no effect of treatment in male mice. (C) No effect of
either acute or chronic α5-PAM treatment in the OFT of either male or female
mice after UCMS. (D) Treatment with acute and chronic α5-PAM reduced the
latency to bite a food pellet in the NSF in female but not male mice.
(E) Chronic α5-PAM treatment reduced the latency to bite a piece of cookie in
the cookie test in female mice, while a trend in the same direction was
observed following acute treatment. No significant effect of α5-PAM was
detected in males. (F) Significant anti-stress effect of both acute and chronic
α5-PAM treatment on female, but not male, Z-emotionality scores, Data
represent mean ± SEM (N = 8–10 per group). ∗p < 0.05, ∗∗p < 0.01.
Additionally, although not statistically significant at 30 min,
pharmacokinetic data indicate elevated accumulation of α5-PAM
in the brain of female compared to male mice during the first
30 min post injection (Figure 1). Therefore we tested a 25%
higher dose (37.5 mg/kg) in males. We found it also failed to
reduce stress-induced behavior across all individual measures in
the EPM, OFT, NSF, and cookie test (Figure 4B; p > 0.05) in
male mice. Composite emotionality Z-scores confirm, similar to
the 30 mg/kg dose (Figure 2E), a lack of anti-stress activity of
37.5 mg/kg α5-PAM (Figure 4D; p> 0.05).
α5-PAM Treatment Increases Gabra5
Transcript Levels in the Prelimbic Cortex
and Hippocampus of Female Mice and
Levels Are Correlated with Stress
Behavior Only in Female Mice
To evaluate the possibility that changes in α5-subunit expression
might explain the sex-specific behavioral effects of treatment,
we assessed levels of α5 gene (Gabra5) and protein expression
within the prelimbic cortex and hippocampus of treated and
untreated UCMS-exposed mice. Results show no difference in
expression of the α5-subunit in either the prelimbic cortex
or hippocampus as a factor of sex following UCMS exposure
(Figures 5A,C, black bars; p > 0.05). In prelimbic cortex, we
observed a significant interaction between sex and treatment
[F(2,32) = 3.508, p < 0.05], with post hoc comparisons
indicating that acute α5-PAM treatment significantly increased
α5 transcript expression in female mice (Figure 5A; p < 0.05).
No effect of chronic treatment was observed in male or female
mice (p > 0.05). In hippocampus, we again observed an
interaction between sex and treatment [F(2,26)= 4.45, p< 0.05],
with post hoc comparisons highlighting an increase in α5-
subunit expression in females after chronic α5-PAM treatment
(Figure 5C; p < 0.01). No changes in Gabra5 gene expression
were observed in males after either acute or chronic α5-PAM
treatment (p > 0.05). Further supporting a link between Gabra5
and stress-induced behavior are significant negative correlations
between expression in the female prelimbic cortex (Figure 5B;
R=−0.622, p< 0.01) and hippocampus (Figure 5D; R=−0.560,
p < 0.05) and Z-emotionality scores. No such significant
correlations were observed in male mice in either the prelimbic
cortex (R = −0.214, p > 0.05) or hippocampus (R = 0.212,
p> 0.05). We next sought to determine whether changes in RNA
expression corresponded to α5 protein levels. We focused on the
hippocampus due to high α5 levels in that region. Surprisingly,
we detected no difference in either total or surface α5 protein
expression following either acute or chronic α5-PAM treatment
in female (Figures 6A,B; p > 0.05) or male mice (Figures 6C,D;
p> 0.05).
DISCUSSION
Treatment with α5-PAM Reduces
Stress-Induced Behavior in Female, but
Not Male Mice
We demonstrate that treatment with a GABAA receptor PAM
with high affinity for α5 subunit-containing subtype (α5-PAM)
(Savic et al., 2010) consistently results in a reduction in
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FIGURE 3 | Treatment with α5-PAM normalizes stress behavior to non-stressed levels in female mice. (A) UCMS reduces the percentage of entries into
the open arms of the EPM. (B) Chronic treatment with α5-PAM increases the percentage of total distance traveled in the center of the open field. (C) UCMS
increases the latency to bite in the NSF compared to NS-VEH treated animals, while both acute and chronic α5-PAM treatment reduces the increased latency
following UCMS. (D) Acute and chronic α5-PAM treatment reduces the latency to bite a piece of cookie in the cookie test compared to UCMS-VEH treated mice.
(E) Overall emotionality Z-score indicates an increase in emotionality in the UCMS-VEH treated mice that is normalized following acute and chronic α5-PAM
administration. Data represent mean ± SEM (N = 15–20 per group). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
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FIGURE 4 | α5-PAM has no anti-stress properties in male mice even after augmenting UCMS with single housing and increased α5-PAM dose.
(A) UCMS combined with isolation housing results in no change in EPM behavior, but a significant decrease in the percentage of distance traveled in the OF, an
increase in the latency to bite the pellet in the NSF, and an increase in latency to bite the cookie in the cookie test. No significant effect in any individual test of chronic
α5-PAM treatment. (B) No change in stress induced behaviors in the EPM, OFT, NSF, or cookie test following acute or chronic treatment with 37.5 mg/kg α5-PAM.
(C) Overall emotionality Z-scores are increased following UCMS-VEH treatment compared to NS-VEH mice. α5-PAM treatment does not remediate the increased
emotionality induced by UCMS in male mice. (D) No effect of acute or chronic α5-PAM on stress-induced behaviors in male mice. Data represent mean ± SEM
(N = 12 per group). ∗p < 0.05, ∗∗p < 0.01.
stress-induced behaviors in female mice exposed to UCMS.
This effect was replicated across two independent cohorts
(Figure 2 and 3). In contrast, treatment with α5-PAM did
not alter stress-induced behaviors in male mice (Figure 2),
even after enhancing the UCMS effect in a second cohort
with isolation housing (Figures 4A,C). The observation that
acute and chronic α5-PAM treatments were effective in
blocking UCMS-induced behavioral emotionality in female mice
(Figures 2 and 3) raises the possibility that targeting the
α5-containing GABAA receptors could have rapid anti-stress
effects.
Pharmacokinetic studies (Figure 1) suggest that the sex-
specific behavioral differences are not likely to be explained
by sex-dependent drug availability. Females displayed time-
dependent elevated α5-PAM plasma levels compared to males
(Figure 1). However, no effect of α5-PAM was observed in
males at times when plasma and total brain levels were similar
to females (30 min; Figure 1) or when a 25% higher dose
of α5-PAM was used (Figure 4). Further,no differences in the
free concentration of brain SH-053-2′F-R-CH3 were observed
at any time point. Together, these data indicate that it is
unlikely our sex-specific behavioral differences were solely due
to pharmacokinetic differences. Note that, even at Tmax, the
estimated free brain concentrations in males (273nM) and
females (313nM) were several times lower than the reported
Ki values of α5-PAM at non-α5-GABAA receptors (Savic et al.,
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FIGURE 5 | Gabra5 transcript expression correlates with stress behavior and is increased after α5-PAM administration in the prelimbic cortex and
hippocampus of female, but not male mice. (A) Acute treatment with α5-PAM increases Gabra5 expression in the prelimbic cortex of female mice exposed to
UCMS. No change in Gabra5 expression was observed following treatment in male mice. (B) Z-emotionality scores significantly correlate with prelimbic cortex
Gabra5 expression in female (top), but not male (bottom) mice (C) Chronic treatment with α5-PAM increases Gabra5 expression in the hippocampus of female mice
exposed to UCMS and compared to animals treated with α5-PAM acutely. No change in Gabra5 expression was observed following either acute or chronic
treatment in male mice. (D) Z-emotionality scores significantly correlate with hippocampal Gabra5 expression in female (top), but not male (bottom) mice. Data
represent mean ± SEM (N = 8–10 per group). ∗p < 0.05, ∗∗p < 0.01.
2010), thus demonstrating selectivity of modulatory action of
the ligand on mouse behavior in the settings used. Despite
slight differences in the effect of acute versus chronic treatment
(Figures 3A–D, Supplementary Figure S1), the data were
qualitatively consistent across cohorts of mice in both sexes
(Figures 2–4).
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FIGURE 6 | No change in either α5 total or surface protein level in the hippocampus of male and female mice. (A,C) Representative blots of two
housekeeping proteins (NK-ATPase, β-Actin) as well as α5 at the surface and total protein levels following UCMS and either vehicle, acute, or chronic α5-PAM
treatment in female (A) or male (C) mice. (B,D). No significant effect of treatment observed on either total or surface α5 protein in female (B) or male (D) mice.
Sex-Dependent Effects of α5-PAM
Treatment Parallel Human
Sex-Dependent Molecular Deficits and
Highlight Modulation of Extrasynaptic
GABAA as a Potential Novel Therapeutic
Modality
The observed sex difference in preclinical testing is potentially
clinically interesting since women are twice as likely than men
to experience a single episode of depression (Kessler, 2003)
and display higher morbidity risk (Piccinelli and Wilkinson,
2000). These differences are not explained by diagnostic
criteria, suggesting a biological predisposition in women (Angst
and Dobler-Mikola, 1984). Interestingly, evidence suggest that
dysfunction in SST interneurons may be more robust in females.
In two frontocortical regions critical for emotion regulation, the
sgACC and dlPFC, decreases in markers of dendritic targeting
interneurons were more pronounced in female MDD compared
to male MDD subjects and their matched controls (Sibille et al.,
2010; Tripp et al., 2011, 2012; Seney et al., 2013). This decrease
in SST expression spanned all cortical layers in the sgACC of
MDD subjects with greater effect sizes and significance in female
subjects, suggesting a cellular vulnerability affecting all cortical
SST neurons in MDD and more robustly in females (Seney et al.,
2014).
In Lin and Sibille (2015), we showed that UCMS specifically
affects expression of SST and GABA synthesizing molecules in
SST neurons. The current pharmacological and behavioral results
indicate that compounds that enhance α5-GABAAR mediated
inhibition postsynaptic to SST cells may overcome or bypass the
impact of the intrinsic vulnerability of SST cells to stress. The fact
that the potential therapeutic action of α5-PAM involves these
cortical deficits is causally supported by our finding that acute
treatment with α5-PAM upregulates expression of the Gabra5
gene exclusively in female mice within the prelimbic cortex
(homologous to the human sgACC), and that levels of the Gabra5
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gene are correlated with lower stress-induced emotionality
behavior. In prelimbic cortex, low expression of total α5 protein
precluded our ability to compare transcript and protein levels.
In the hippocampus, where α5 mRNA and protein are highly
expressed, we observed an increase in transcript expression
following chronic α5-PAM treatment in female mice and, as
in the cortex, a negative correlation between Gabra5 transcript
levels and emotionality behavior, suggesting an important role
for Gabra5 in stress-induced behaviors (Figures 5C,D). However,
no corresponding change in either total or surface protein level
was observed (Figure 6). Contributing to this discrepancy may
be the fivefold to sixfold increase in protein half-life relative
to mRNA, which results in greater dynamic mRNA regulation
(Schwanhausser et al., 2011), or simply that at the time of
sacrifice, translation of the α5 transcript was not elevated.
It is worth noting that chronic α5-PAM treatment in female
mice produced anti-stress effects with no down-regulation of
the Gabra5 transcript, commonly observed following chronic
benzodiazepine administration (Uusi-Oukari and Korpi, 2010),
which potentially explains the development of drug tolerance to
benzodiazepine-like pan-GABAA receptor modulators (Vinkers
and Olivier, 2012). In fact, sustained upregulation of α5 protein
has been reported after exposure to anesthetics that act primarily
as GABAA receptor modulators (Zurek et al., 2014). These
findings further highlight the specificity of α5-PAM for α5-
subunit containing GABAA receptors and alleviate concerns
regarding a decrease in efficacy following chronic treatment.
Converging evidence from clinical data suggests an
involvement of extrasynaptic GABAA receptors in psychiatric
illness. Linkage studies have identified a susceptibility locus
within the GABRA5 gene (15q11-q13) for bipolar depression
(Otani et al., 2005; Kato, 2007). Post-mortem studies have
further examined the link between GABRA5 gene expression
and depression, with mixed findings. In the ACC and dlPFC,
data suggest that expression of the GABRA5 gene is increased in
cortical layers 2–6 of subjects with bipolar depression and those
with MDD (Choudary et al., 2005). In post-mortem dlPFC tissue
from depressed suicides, no difference in GABRA5 expression
was observed (Merali et al., 2004). Similarly, in the amygdala of
female post-mortem subjects, where decreases in SST and other
GABA interneuron markers are present, no change in GABRA5
gene expression was observed between MDD and matched
controls (Guilloux et al., 2012). While this is the first study to
demonstrate anti-stress effects of a selective α5-PAM compound,
other studies have found that compounds with mixed α5 and
α2 specificity do have anxiolytic effects in rodents (Savic et al.,
2008, 2010). Moreover a recent study in the amygdala suggests
that generalization of fear and anxiety is mediated by α5-subunit
containing neurons in the central nucleus of the amygdala (Botta
et al., 2015). Consistent with the role of the α5-subunit in anxiety,
the anxiolytic effect of diazepam was manifest in mice rendered
insensitive to its modulatory action at all GABAAR subunits
other than α5-GABAARs (Behlke et al., 2016). Taken together,
the data support a potential role for the α5-GABAA receptor in
stress-associated disorders, including anxiety and depression,
though it is an area to study further, especially as it pertains to
potential sex differences.
Data characterizing the expression of α5-GABAA receptors
in stress models are sparse, and our report is the first to
examine potential sex-specific effects. Previous reports suggest
that expression of the α5-subunit is increased in the frontal cortex
following prolonged social isolation in male mice (Matsumoto
et al., 2007). Expression of another extrasynaptic GABAA
receptor subunit, the δ-subunit, is also increased after social
isolation, a finding that correlates with increased tonic inhibition
(Serra et al., 2006). A notable difference, however, is that the
δ-subunit is not restricted to the dendritic compartment, as is the
case for the α5-containing GABAA receptors (see Introduction).
Interestingly, expression of extrasynaptic δ-GABAA receptor
is modulated across the estrous cycle and sensitive to the
neurosteroid progesterone, an effect that is rapid and does not
require activation of neurosteroid receptors (Maguire et al.,
2005; Maguire and Mody, 2007). Expression of extrasynaptic
GABAA receptors is decreased at parturition and increased
postpartum, providing support for hormonal modulation of
these extrasynaptic receptors. Further, estrogen treatment itself
has long been known to upregulate GABAA receptors in the
brain of rodents (Maggi and Perez, 1986), though a complete
evaluation of the exact subunit combinations altered has not been
conducted. Given our observed sex specific effects of treatment
with α5-PAM, it is reasonable to hypothesize that interaction with
circulating steroid hormones (e.g., estrogens) and extrasynaptic
GABAA receptors (e.g., containing the α5 and δ-subunits),
may be influencing this finding. Further supporting this notion
is our finding that acute and chronic treatments selectively
upregulate α5-GABAA receptor expression in the prelimbic
cortex and hippocampus (Figure 5). Together, these preclinical
data support the involvement of extrasynaptic GABAA receptors
in the stress response and indicate sex-specific regulation of
receptor expression.
Limitations
The present study, while potentially suggesting a novel sex-
dependent therapeutic modality for antidepressant treatment, is
not without limitations. The authors acknowledge the inherent
variability of the UCMS procedure, where the phenotype typically
ranges in severity and may not be observed systematically
and statistically in every single behavioral test, when analyzed
in isolation (Guilloux et al., 2011). This variability mirrors
what is observed in MDD, where diagnosis is not based on
a single observable behavior, but rather a convergent set of
symptoms from multiple measures across multiple time points
(e.g., physiological/somatic symptoms and affective symptoms).
For this reason we have adopted a Z-normalization procedure
to assess the consistency of behavior across tests and to increase
the translational value of the UCMS model (Surget et al., 2009;
Edgar et al., 2011; Guilloux et al., 2011; Quesseveur et al.,
2015). Harnessing this approach, we demonstrate that in multiple
cohorts, despite modest effect size and minor differences in
significance across specific tests, α5-PAM treatment in female
animals consistently normalized stress behaviors (Figures 2
and 3) while male animals were unaffected (Figures 2 and 4). An
additional limitation is the use of multiple injections separated by
48 h for our acute α5-PAM treated mice. While pharmacokinetic
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data indicate no drug should remain in either the plasma
or brain 48 h after a single injection (Figure 1), we cannot
rule out the possibility that a single injection resulted in a
lasting neuroplastic change that could have been compounded
by subsequent injections. Regardless, this factor did not impact
our ability to detect sex-dependent behavioral differences in stress
behavior (Figures 2–4).
Therapeutic Potential of Targeting
α5-Containing GABAA Receptors
Here, we demonstrate that a GABAA α5-selective PAM can
reduce stress behavior induced by UCMS to non-stressed levels
when administered acutely and chronically to female mice
(Figures 2 and 3). The effect on anxiety-like behaviors in
females was mild, although behavioral Z-score normalization
identified consistent behavioral responses across tests, and it
was replicated across two independent cohorts (Figures 2
and 3). By contrast, we observed a consistent lack of
effect in male mice across separate cohorts, regardless of
treatment regimen or dose (Figures 4C,D). This lack of effect
in males was not explained by pharmacokinetic differences
(Figure 1). These data confirm previous reports indicating a
lack of anxiogenic/anxiolytic properties of specific α5-subunit
modulation in male rodents either pharmacologically (Savic
et al., 2008, 2010) or genetically (Collinson et al., 2002),
although a recent restriction of GABAA-subtype function
experiment in male mice suggests α5-mediated anxiolysis (Behlke
et al., 2016). Interestingly, a recent study in male rats found
that two negative allosteric modulators (NAM) selective for
the α5-subunit could reverse stress-induced anhedonia and
deficits in AMPAR-mediated synaptic transmission within the
hippocampus (Fischell et al., 2015). While these findings
appear at odds with the data presented here, with preclinical
studies suggesting anxiogenic effects of α5-NAMs (Navarro
et al., 2002), and with the clinical and human post-mortem
literature, they are in accordance with the actions of the rapid-
acting antidepressant ketamine (Berman et al., 2000; Li et al.,
2010; Autry et al., 2011). Together, these studies suggest that
basal GABA tone or baseline cellular activity, for which sex
may be a mediating factor, may influence which type of α5-
modulator (positive or negative) may produce a therapeutic
benefit. Support for this contention comes from the finding that
while α5 GABAA receptor NAMs enhance memory in young
rats, positive modulation is necessary to improve memory in
older rats with excessive hippocampal activity and decreases in
α5 transcript expression (Haberman et al., 2011; Koh et al.,
2013). We believe that the same principle may exist in the
UCMS condition, where animals are in a low GABA state
due to dysfunction of SST cells (Lin and Sibille, 2015), and
potentially in MDD where low GABA content and dendritic
targeting interneuron dysfunction is observed in analogous brain
regions.
CONCLUSION
In summary, the present study supports the hypothesis that
enhancing signaling specifically at α5-GABAA receptors may
represent a novel therapeutic approach for mood disorders,
including anxiety and depression. Interestingly, this treatment
approach may be more beneficial to women, who are more
severely affected by MDD. Future experiments should further
explore the sex-dependent effects of treatment and propose the
exact mechanism by which modulation of α5-GABAA receptors
is exerting its effects in the UCMS condition.
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